natgillin/translations-raw huggingface dataset:
or a pharmaceutically acceptable salt thereof, comprising the following steps: reaction of an amino-protected 1-amino-1-hydroxymethylcyclopropane of formula (VI): 
ili odgovarajuće farmaceutski pirihvatljive soli, naznačen time da obuhvaća sljedeće korake: a) reakciju 1-amino-1-hidroksimetilciklopropana formule (VI) čija je amino-skupina zaštićena: x
A method for producing a defined population of binding molecules, said method comprises at least the following steps: 
Postupak za proizvodnju najmanje dva antitijela koja se vezuju za odabrani antigen ili epitop od interesa, pri čemu navedeni postupak sadrži najmanje slijedeće korake:
A method according to claim 16, wherein said conditions or disease associated with obesity, overweight or abnormal fat-distribution are selected from the group consisting of diabetes, cardiovascular diseases, obstructive sleep apnea, lipoma, cancer, osteoarthritis, endocrinologic disease and disorders, reproductive disease and disorders, neurological diseases and disorders, psychiatric diseases and disorders, rheumatological diseases and disorders and orthopedic disease and disorders. 
Spoj za uporabu sukladno zahtjevu 8, pri čemu su navedena stanja ili bolesti povezane s pretilošću, prekomjernom tjelesnom težinom ili abnormalnom distribucijom masnog tkiva odabrana iz skupine dijabetesa, kardiovaskularnih bolesti, opstruktivne apneje sna, lipoma, karcinoma, osteoartritisa, endokrinoloških oboljenja i poremećaja, reproduktivnih bolesti i poremećaja, neuroloških bolesti i poremećaja i ortopedskih bolesti i poremećaja.
• addition and agitation of water and baking powder, 
dodavanje i miješanje vode i pekarskog proizvoda, .
The variant of claim 7, comprising the substitution K32E. 
Varijanta iz zahtjeva 7, naznačena time, da sadrži supstituciju K32E.
Since the present composition must be suitable for use in beverages and foodstuffs, said composition should not include appreciable amounts of non-food grade organic solvents such as those commonly used to dissolve chemicals. 
Budući da sadašnji pripravak mora biti prikladan za upotrebu u pićima i prehrambenim proizvodima, spomenuti pripravak ne bi trebao sadržavati mjerljive količine ne-prehrambenih organskih otapala, kao što su ona koja se obično upotrebljavaju za otapanje kemikalija.
The pharmaceutical composition of claim 5, wherein the ratio of AvPAL variant and the polyethylene glycol is about 1:3. 
Farmaceutski sastav iz patentnog zahtjeva 8, pri čemu je omjer navedene AvPAL varijante i polietilen glikola oko 1:3 (1:3 AvPAL:PEG).
pharmaceutically acceptable salts, solvates, esters, and/or stereoisomers thereof. 
N ili njegovih farmaceutski prihvatljivih soli, solvata, estera, i/ili stereoizomera.
An ultrasonic handpiece system, comprising: 
Sustav ultrazvučnog ručnog uređaja koji sadrži:
A cervical pessary according to claim 1, wherein the amount of progesterone sustained and continuously released from the pessary is of 15 mg to 65 mg daily, for a period of at least 6 months. 
Cervikalni pesar prema zahtjevu 1, naznačen time što je količina progesterona neprekidno i kontinuirano oslobođenog iz pesara od 15 mg do 65 mg dnevno, tijekom perioda od barem 6 mjeseci.
In yet another embodiment, an aforementioned method is provided further comprising the step of reducing an oxime linkage in the conjugated therapeutic protein by incubating the conjugated therapeutic protein in a buffer comprising a reducing compound selected from the group consisting of sodium cyanoborohydride (NaCNBH3), ascorbic acid (vitamin C) and NaBH3. 
Postupak prema bilo kojem od zahtjeva 1-16, koji dalje sadrži korak reduciranja vezanja oksima kod konjugiranog terapeutskog proteina inkubiranjem konjugiranog terapeutskog proteina u puferu koji sadrži reduciranje spoja odabranog od skupine koja se sastoji od natrij cijanoborohidrida (NaCNBH>), askorbinske kiseline (vitamin C) i NaBH.:.
A compound for use according to claim 9, wherein the helminth is selected from the group consisting of Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubriformis, Cooperia curticei, Nematodirus battus and combinations thereof. 
Ariloazol-2-il-cijanoetilamin za uporabu prema zahtjevu 12, naznačen time, da helmint je Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubrifromis, Cooperia curtcei, Nematodirus Battus, i njihove kombinacije.
An isolated peptide of less than about 15 amino acids selected from the group consisting of peptides comprising the amino acid sequences of SEQ ID NO: 376, 379, 114, 116, 117, 121, 227, 228, 233, 254, 271, 272 or 288. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78, u kojima je jedna aminokiselina zamijenjena, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
injecting gas into the pretreated sewn ball obtained by the step (5) to form a round ball, putting the round ball into a reshaping mould, pressurizing and reshaping with a pressure of 3-10 kg/cm2, a time of 1-8 min, and a mould temperature of 30-70 °C for attaching the housing to the surface of the inner tube (5), and cleaning a surface of the housing (4), thereby obtaining the sewn ball, wherein a circumferential error of the sewn ball is less than 2 mm. 
(6) injektiranje plina u predobrađenu zašivenu loptu koja je dobivena u koraku (5) u svrhu oblikovanja okrugle lopte, stavljanje okrugle lopte u kalup za ponovno oblikovanje, tlačenje 1 ponovno oblikovanje s tlakom od 3 do 10 kg/cm', u vremenu od 1 do 8 min, i na temperaturi kalupa od 30 do 70%C, za pričvršćivanje omotača na površinu unutrašnjeg balona (5), te čišćenje površine omotača (4), a time dobivanje zašivene lopte, pri čemu je pogreška obujma ponovno oblikovane zašivene lopte manja od 2 mm.
which is connected to the antibody at position 3 thereof and is connected to a methylene group in the linker structure containing this structure on the nitrogen atom at position 1, and (NH-DX) represents a group represented by the following formula: 
koja je povezana sa anti-HER2 antitijelom na svojoj poziciji 3 i povezana je sa metilenskom grupom u strukturi veznika pri čemu sadrži ovu strukturu na atomu dušika na poziciji 1.
At least one basin may be provided with a system of pipes conducting wastewater between the basin and the pumping system. 
Sustav sukladno bilo kojem od patentnih zahtjeva 5 do 12, naznačeno time da najmanje jedan bazen ima sustav cijevi (28a, 28b) za provođenje otpadne vode između bazena i sustava za pumpanje.
The eluent is concentrated and purified by HPLC-MS to give the title compound as a white solid. 
Eluens se koncentrira, te pročisti HPLC-MS-om kako bi se dobilo naslovni spoj u obliku bijeli krutina.
it has a galactosylation degree on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition, that is increased compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from ATCC No. 
(1i) stupanj galaktoziliranja na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod molekula proteina u navedenom pripravku s molekulom proteina mu je povećan u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
The pharmaceutical composition of claim 3 or 4, wherein the at least one additional therapeutic agent is selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, other drugs for treating HCV, and combinations thereof. 
Spoj formule IIBb [image] ili njegova farmaceutski prihvatljiva sol ili solvat, u kombinaciji s jednim ili više dodatnih terapeutskih sredstava izabranih iz grupe koju čine spojevi inhibitori HIV proteaze, HIV nenukleozidni inhibitori reverzne transkriptaze, HIV nukleozidni inhibitori reverzne transkriptaze, HIV nukleotidni inhibitori reverzne transkriptaze, inibitori HIV integraze, inhibitori gp41, inhibitori CXCR4, inhibitori gp120, inhibitori G6PD i NADH-oksidaze, inhibitori CCR5, drugi lijekovi za liječenje HIV-a, i njihove mješavine, za upotrebu u liječenju HIV infekcije.
The transgenic mouse of claim 1, wherein the replacement comprises endogenous mouse Vλ gene segments of the second endogenous Vλ-Jλ-Cλ gene cluster have been replaced with a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ3-27 gene segment to a human Vλ3-1 gene segment and a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ5-52 gene segment to a human Vλ1-40 gene segment. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
part B which comprises at least 1 B-aggregating region and wherein said region is derived from said protein to be downregulated. 
dio B koji sadrži barem jedno B-agregacijsko područje i pri čemu je navedeno područje dobiveno iz navedenog proteina koji treba podregulaciju.
Sleep-wake recording criteria included wakefulness (W), light slow wave sleep (SWS1), deep SWS (SWS2) and paradoxical sleep (PS). 
Kriteriji za bilježenje budnosti-spavanja uključuju budnosti (W, prema engleskom"wakefulness"), lagani san sporih valova (SWS1, prema engleskom,,slow wave sleep"), duboki SWS (SWS2) i paradoksni san (PS, prema engleskom,,paradoxical sleep").
a humectant selected from glycerol, propylene glycol, cetyl alcohol, glycerin monostearate and polyethylene glycols, or a combination thereof; and 
ovlaživač odabran od glicerola, propilen-glikola, cetilnog alkohola, glicerin-monostearata i polietilen-glikola, i njihovih kombinacija; i
An antisense oligomer which is selected from a group consisting of (a) to (d) below, or a pharmaceutically acceptable salt or hydrate thereof: 
Antisensni oligomer odabran iz skupine sastvaljene od (4) dolje, ili njegove farmaceutski prihvatljive soli ili hidrata:
The use according to claim 22, wherein the δ-amino-y-hydroxy-w-aryl-alkanoic acid amide derivative is a compound of formula (I) wherein R1 is 3-methoxypropoxy; R2 is methoxy; and R3 and R4 are isopropyl; or a pharmaceutically acceptable salt thereof. 
Uporaba u skladu sa zahtjevom 22, naznačena time, da derivat amida 8-amino-y-hidroksi-o-aril-alkanoične kiseline je spoj formule (1) gdje Ri je 3-metoksipropoksi; R> je metoksi; te Rs i Re su izopropil; ili je njegova farmaceutski prihvatljiva sol.
The liposome injection according to claim 17, characterized in that the said injection is lyophilized powder for injection which comprises a lyoprotectant, and is prepared by freeze-drying. 
Injekcija liposoma prema zahtjevu 15, naznačena time što je ta injekcija liofilizirani prašak za injekciju koji sadrži lioprotektant i priprema se sušenjem putem zamrzavanja.
the ceftriaxone or the pharmaceutically acceptable salt thereof, is present in an amount of about 0.25 g, calculated as ceftriaxone free acid, 
(a) ceftriakson natrij u količini od 0.25 g, preračunato kao cefiriaksonska slobodna kiselina,
The method of claim 20, wherein the one or more cancer cells are deficient in one or more of ATM, Rad51, Rad52, Rad54, Rad50, MRE11, NBS1, XRCC2, XRCC3, cABL, RPA, CtIP, and MBC. 
deficitarnih u pogledu proteina uključenih u popravak DBS-a DNK putem HR-a, pri čemu su stanice raka opcionalno deficitarne u pogledu ATMA, Rad51, Rad52, Rad54, Rad50, MREI1, NBS1, XRCC2, XRCC3, CABL, RPA, CtIP i MBC.
For example, intermediate 1 and analogous compounds can be converted to their corresponding N-methyl derivatives by reaction with formaldehyde and sodium cyanoborohydride. 
Na primjer, intermedijer 1 i analogni spojevi mogu se prevesti u njihove odgovarajuće N-metil derivate reakcijom s formaldehidom i natrijevim cijanoborhidridom.
sheet material forming apparatus for forming at least one sheet material; cutting means for cutting said sheet into napkins; and 
sredstva za rezanje za rezanje navedenog lista materijala u ubruse; i uređaj prema zahtjevu 1 ili zahtjevu 2
A compound according to claim 8, wherein Ray, Rby and Rcy are independently selected from hydrogen and methyl. 
Spoj prema patentnom zahtjevu 5, naznačen time što su Ray, Rby i RCy nezavisno izabrani od vodika i metila.
The nucleic acid as claimed in claim 11 wherein the nucleotide sequence encoding the polypeptide comprising a heavy chain variable region has the sequence of SEQ ID NO: 11, and the nucleotide sequence encoding the polypeptide comprising a light chain variable region has the sequence of SEQ ID NO: 12. 
Nukleinska kiselina prema zahtjevu 11, naznačena time, da nukleotidna sekvenca koja kodira polipeptid s varijabilnim područjem jakog lanca, ima sekvencu od SEQ ID NO:11, i nukleotidna sekvenca koja kodira polipeptid s varijabilnim područjem slabog lanca, ima sekvencu od SEQ ID NO:12.
The method according to any one of claims 1 to 9, wherein the cell density is maintained at less than 2.5x106 cells per mL during the step of culturing the one or more cells, less than 2.0x106 cells per mL during the step of culturing the one or more cells, or less than 1.5x106 cells per mL during the step of culturing the one or more cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što se gustoću stanica održava kod manje od 2,5 x 106 stanica na ml u koraku uzgoja jedne ili više stanica, manje od 2,0 x 106 stanica na ml u koraku uzgoja jedne ili više stanica, ili manje od 1,5 x 106 stanica na ml u koraku uzgoja jedne ili više stanica.
The solid formulation according to Claim 1, wherein a volume average primary particle size of the core particles is 5 µm to 1000 µm. 
Čvrsta formulacija prema zahtjevu 1, naznačena time, da prosječni volumen primarne veličine čestice od jezgrenih čestica, iznosi od 5 um do 1000 um.
a sealing member (3) including: 
- < element za brtvljenje (3) koji sadrži:
having the formula:; or 
(iv) ima sljedeću formulu:
In the method, the telomere length component is a positive component when calculating the percentage change. 
Postupak prema zahtjevu 4, pri čemu je komponenta duljine telomere pozitivna komponenta prilikom računanja postotka promjene.
Packaging unit according to one or more of the foregoing claims, wherein the label further comprises a number of glue edges (38). 
Jedinica za pakiranje prema jednom ili više od prethodnih zahtjeva, naznačena time da naljepnica nadalje sadrži veći broj lijepljenih rubova (38).
A composition comprising the cell-binding agent maytansinoid conjugate of claim 1, and a pharmaceutically acceptable carrier, diluent or excipient. 
Sastav, naznačen time, da obuhvaća sredstvo za vezanje stanice konjugata majtanzinoida prema zahtjevu 1, i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćno sredstvo.
transfecting the linearized DNA into mammalian cells; 
(e) transfekciju linearizirane DNK u stanice sisavca;
A pharmaceutical composition comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to 400 µg (plus/minus 10%) aclidinium bromide for use by inhalation in the treatment of chronic obstructive pulmonary disease. 
HR P20151214 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak koji sadrži aklidinij u obliku suhog praha farmaceutski prihvatljive soli u smjesi s farmaceutski prihvatljivim nosačem suhog praha, pružajući odmjerenu nominalnu dozu aklidinija jednaku 400 ug (plus/minus 10 %) aklidinijevog bromida za primjenu inhalacijom u liječenju kronične opstruktivne plućne bolesti.
wherein the substrate comprises a material including a substantially open-celled structure such that gas and/or vapour can be displaced from the pressing region. 
gdje nosivi materijal obuhvaća materijal čija je struktura u biti otvorenih pora, kako bi se plin i/ili para mogli odstranjivati s područja stlačivanja.
The use of claims 6-11 wherein the device reduces the patient's demand for systemic analgesia. 
Uporaba iz patentnih zahtjeva 6-11 pri čemu naprava umanjuje pacijentovu potrebu za sustavnom analgezijom.
In a preferred embodiment, the invention relates to a protein or polypeptide or peptide which comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-14, and 146-150, a part or derivative thereof. 
Uporaba protutijela u metodi za detekciju tumorskih stanica koje eksprimiraju antigen povezan s tumorom, pri čemu se protutijelo veže na antigen povezan s tumorom, pri čemu se protutijelo može dobiti imunizacijom s peptidom ili polipeptidom koji ima sekvencu aminokiselina odabran iz skupine koja se sastoji od SEQ ID NO:
The single-handle dual-control thermostatic faucet according to any preceding claim, wherein a hot water feed pipe and a cold water feed pipe are included, both of which are respectively connected to the hot water and cold water inlets of the valve body. 
Termostatska slavina s jednom ručkom i dvojnom kontrolom u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su uključene cijev za dovod vruće vode (41) i cijev za dovod hladne vode (42), od kojih su obje odgovarajuće povezane s ulazom vruće vode i ulazom hladne vode (81, 82) na tijelu ventila.
The method of claim 1, wherein the compound is 8-(ethyl-D5)-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 8-(etil-D5)-6-(trifluorometoksi)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
An intravenous (i.v.) 
3) Intravenozna (i.v.)
a final concentration of about 1% to about 5% w/v of a mixture of two reducing monosaccharides, (ii) a final concentration of about 0.1% to about 0.3% w/v of at least one acid antioxidant, and (iii) a final concentration of about 0.5% to about 7.5%w/v of at least one bulking agent or 
(a) (1) konačnu koncentraciju od oko 1% do oko 5% tež.Avol. smjese dva redukcijska monosaharida, (ii) konačnu koncentraciju od oko 0.1% do oko 0.3% tež./vol. najmanje jednog kiselog antioksidansa, i (iii) konačnu koncentraciju od oko 0.5% do oko 7.5% tež.Avol. najmanje jednog punila ili
Source: Wistar rat brain 
Izvor: mozak Wistar štakora
Per day Number of Cigarettes per day 
(21) Broj predmeta:
A method for making a host cell for production of a heterodimeric CH3 domain-comprising molecule, the method comprising the step of introducing into said host cell nucleic acid sequences encoding at least a first and a second human IgG CH3 domain-comprising polypeptide chain, wherein said first CH3 domain-comprising polypeptide chain comprises a lysine (K) residue at amino acid position 366 according to the EU numbering system and wherein said second CH3 domain-comprising polypeptide chain comprises an aspartic acid (D) residue at amino acid position 351 according to the EU numbering system, wherein said nucleic acid sequences are introduced consecutively or concomitantly. 
Postupak za pripremu stanice domaćina za proizvodnju najmanje dva različita antitijela, pri čemu postupak sadrži korak uvođenja u navedenu stanicu domaćina sekvenci nukleinske kiseline koje kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizinski (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije, pri čemu navedene sekvence nukleinske kiseline su uvedene uzastopno ili istovremeno.
The method according to claim 2 wherein said heavy chain has SEQ ID NO:164 and said light chain has SEQ ID NO:169. 
Pripravak prema zahtjevu 2 ili 3, naznačen time što navedeni teški lanac ima SEQ ID NO: 164, a navedeni laki lanac ima SEQ ID NO: 169.
The pharmaceutical composition according to claim 4, further comprising additional active compound. 
Farmaceutska smjesa prema zahtjevu 4, dalje sadrži dodatnu djelatnu tvar.
Further, while the exemplary diagrams show an isobutyl sidechain, it should be appreciated that other groups may be substituted for the various substituents in the formulas of Scheme 8. 
Nadalje, dok dijagrami koji su prikazani kao primjer imaju izobutilni bočni lanac, trebalo bi uvažiti da druge skupine mogu biti supstituirane s različitim supstituentima u formulama iz sheme 8.
The compound according to claim 1, wherein said compound has formula IV: 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu IV:
particular combinations of the present invention include: 
Broj objave europske prijave patenata:
The used adhesive formulation was a one-component polyurethane adhesive of the company Collano AG with a processing time (open time) of approximately 7 minutes. 
Po formulaciji je upotrijebljeno ljepilo bilo jedno-komponentno poliuretansko ljepilo kompanije Collano AG s vremenom za rad (otvoreno vrijeme) od približno 7 minuta.
The synthetic method includes the following steps: combining a composition comprising an amine-terminated or hydroxy-terminated, water-soluble polymer with a composition comprising an activated carbonate reagent, optionally in the presence of a catalyst or acid-neutralizing base, wherein the composition comprising the activated carbonate reagent is added such that there is an excess of the activated carbonate reagent relative to the amine-terminated or hydroxy-terminated, water-soluble polymer, to thereby result in a composition comprising an active carbonate ester of the water-soluble polymer and unreacted activated carbonate reagent; and 
(b) dodavanje, prije rekuperacije aktivnog karbonatnog estera vodotopljivog polimera, kompozicije koja sadrži reaktivnu molekulu i koja je izabrana iz grupe koja se sastoji od vode, nižeg alkil monohidroksilnog alkohola, vodikova sulfida i nižeg alkil monobaznog amina, kompoziciji koja sadrži aktivni karbonatni ester vodotopljivog polimera i neizreagirani aktivirani karbonatni reagens, pri čemu se kompozicija koja sadrži reaktivnu molekulu dodaje tako da se potroši više od 50% neizreagiranog aktiviranog karbonatnog reagensa.
The pharmaceutical composition of claim 25, wherein said at least one antiviral agent is ribavirin and said at least one interferon is a-interferon or pegylated interferon. 
Farmaceutski pripravak u skladu s patentnim zahljevom 25, naznačen time što navedeno najmanje jedno protuvirusno sredstvo je ribavirin, a navedeni najmanje jedan interferon je a-interferon ili pegilirani interferon.
Figure 1 is a schematic view from above of the sanding element according to the invention. 
Slika 1 je shematski prikaz elementa za brušenje koji je u skladu s ovim izumom, gledan s gornje strane.